Similar articles for PMID: 31085680

Year	Number of Results
2005	1
2007	3
2008	2
2009	2
2010	1
2011	5
2012	4
2013	15
2014	14
2015	15
2016	16
2017	14
2018	7
2019	9
2020	1
2021	2

1

Dual Inhibition of Gastrointestinal Phosphate Absorption: More Questions Than Answers.

Yeung WG, Toussaint ND, Badve SV. Yeung WG, et al. J Am Soc Nephrol. 2019 Jun;30(6):909-910. doi: 10.1681/ASN.2019040333. Epub 2019 May 13. J Am Soc Nephrol. 2019. PMID: 31085680 Free PMC article. No abstract available.

2

Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE Trial.

Ix JH, Isakova T, Larive B, Raphael KL, Raj DS, Cheung AK, Sprague SM, Fried LF, Gassman JJ, Middleton JP, Flessner MF, Block GA, Wolf M. Ix JH, et al. J Am Soc Nephrol. 2019 Jun;30(6):1096-1108. doi: 10.1681/ASN.2018101058. Epub 2019 May 13. J Am Soc Nephrol. 2019. PMID: 31085679 Free PMC article. Clinical Trial.

3

The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis.

Habbous S, Przech S, Acedillo R, Sarma S, Garg AX, Martin J. Habbous S, et al. Nephrol Dial Transplant. 2017 Jan 1;32(1):111-125. doi: 10.1093/ndt/gfw312. Nephrol Dial Transplant. 2017. PMID: 27651467 Review.

4

Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.

Navaneethan SD, Palmer SC, Craig JC, Elder GJ, Strippoli GF. Navaneethan SD, et al. Am J Kidney Dis. 2009 Oct;54(4):619-37. doi: 10.1053/j.ajkd.2009.06.004. Epub 2009 Aug 18. Am J Kidney Dis. 2009. PMID: 19692157 Review.

5

[Strategies aiming to control hyperphosphatemia in chronic kidney disease].

Ureña Torres PA. Ureña Torres PA. Nephrol Ther. 2017 Apr;13 Suppl 1:S95-S101. doi: 10.1016/j.nephro.2017.01.002. Nephrol Ther. 2017. PMID: 28577750 Review. French.

6

An Update on Phosphate Binders: A Dietitian's Perspective.

Gutekunst L. Gutekunst L. J Ren Nutr. 2016 Jul;26(4):209-18. doi: 10.1053/j.jrn.2016.01.009. Epub 2016 Feb 23. J Ren Nutr. 2016. PMID: 26920090 Review.

7

Can we IMPROVE cardiovascular outcomes through phosphate lowering in CKD? Rationale and protocol for the IMpact of Phosphate Reduction On Vascular End-points in Chronic Kidney Disease (IMPROVE-CKD) study.

Lioufas N, Toussaint ND, Pedagogos E, Elder G, Badve SV, Pascoe E, Valks A, Hawley C; IMPROVE-CKD Writing Committee.. Lioufas N, et al. BMJ Open. 2019 Feb 21;9(2):e024382. doi: 10.1136/bmjopen-2018-024382. BMJ Open. 2019. PMID: 30796122 Free PMC article. Clinical Trial.

8

Efficacy and safety of lanthanum carbonate in pre-dialysis CKD patients with hyperphosphatemia: a randomized trial.

Takahara Y, Matsuda Y, Takahashi S, Shigematsu T; Lanthanum Carbonate Study Group. Takahara Y, et al. Clin Nephrol. 2014 Sep;82(3):181-90. doi: 10.5414/cn108269. Clin Nephrol. 2014. PMID: 25079863 Clinical Trial.

9

Effects of lanthanum carbonate and calcium carbonate on fibroblast growth factor 23 and hepcidin levels in chronic hemodialysis patients.

Chang YM, Tsai SC, Shiao CC, Liou HH, Yang CL, Tung NY, Hsu KS, Chen IL, Liu MC, Kao JL, Jhen RN, Huang YT. Chang YM, et al. Clin Exp Nephrol. 2017 Oct;21(5):908-916. doi: 10.1007/s10157-016-1362-9. Epub 2016 Dec 7. Clin Exp Nephrol. 2017. PMID: 27928636 Clinical Trial.

10

Prevention and treatment of hyperphosphatemia in chronic kidney disease.

Vervloet MG, van Ballegooijen AJ. Vervloet MG, et al. Kidney Int. 2018 May;93(5):1060-1072. doi: 10.1016/j.kint.2017.11.036. Epub 2018 Mar 23. Kidney Int. 2018. PMID: 29580635 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed